NL300269I1 - Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes. - Google Patents

Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.

Info

Publication number
NL300269I1
NL300269I1 NL300269C NL300269C NL300269I1 NL 300269 I1 NL300269 I1 NL 300269I1 NL 300269 C NL300269 C NL 300269C NL 300269 C NL300269 C NL 300269C NL 300269 I1 NL300269 I1 NL 300269I1
Authority
NL
Netherlands
Prior art keywords
disintegrated
particles
preparation
human papillomavirus
papillomavirus vaccine
Prior art date
Application number
NL300269C
Other languages
English (en)
Other versions
NL300269I2 (nl
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300269(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NL300269I1 publication Critical patent/NL300269I1/nl
Publication of NL300269I2 publication Critical patent/NL300269I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NL300269C 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin NL300269I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles
PCT/US2000/007595 WO2000057906A1 (en) 1999-03-26 2000-03-22 Human papillomavirus vaccine with disassembled and reassembled virus-like particles

Publications (2)

Publication Number Publication Date
NL300269I1 true NL300269I1 (nl) 2007-05-01
NL300269I2 NL300269I2 (nl) 2008-07-01

Family

ID=26824774

Family Applications (3)

Application Number Title Priority Date Filing Date
NL300270C NL300270I1 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.
NL300268C NL300268I1 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.
NL300269C NL300269I2 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NL300270C NL300270I1 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.
NL300268C NL300268I1 (nl) 1999-03-26 2007-03-13 Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.

Country Status (19)

Country Link
US (2) US6245568B1 (nl)
EP (1) EP1165126B1 (nl)
JP (1) JP4594534B2 (nl)
KR (1) KR20020013516A (nl)
AR (1) AR023166A1 (nl)
AT (1) ATE339222T1 (nl)
AU (1) AU778937B2 (nl)
CA (1) CA2368391C (nl)
CY (4) CY1105779T1 (nl)
DE (4) DE122007000033I1 (nl)
DK (1) DK1165126T3 (nl)
ES (1) ES2270822T3 (nl)
FR (1) FR07C0026I2 (nl)
LT (1) LTC1165126I2 (nl)
LU (3) LU91327I2 (nl)
NL (3) NL300270I1 (nl)
PT (1) PT1165126E (nl)
SI (1) SI1165126T1 (nl)
WO (1) WO2000057906A1 (nl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
ES2325053T3 (es) * 1999-12-09 2009-08-25 Medimmune, Llc Metodo in vitro para desensamblaje/reensamblaje de particulas similares a virus de papilomavirus (vlp).
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003278166B2 (en) 2002-11-01 2009-01-29 Glaxosmithkline Biologicals S.A. Immunogenic composition
MY144492A (en) 2002-12-20 2011-09-30 Glaxosmithkline Biolog Sa Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
EP1785433A4 (en) * 2004-07-01 2008-10-01 Tokyo Inst Tech VIRUS PARTICULAR CONSTRUCT AND METHOD FOR THEIR EDUCATION UNDER PHYSIOLOGICAL CONDITIONS
BRPI0607269A2 (pt) * 2005-01-25 2009-08-25 Wyeth Res Ireland Ltd protetores de cisalhamento para colheita por microfiltragem
WO2007011711A2 (en) * 2005-07-14 2007-01-25 Mayo Foundation For Medical Education And Research Paramyxoviridae virus preparations
US20090105130A1 (en) * 2005-08-12 2009-04-23 Astellas Pharma Inc. Depsipeptide-containing injection solution
WO2007027076A1 (es) * 2005-09-01 2007-03-08 Nuno Ayala Jose Luis Formula estabilizadora de vacunas con antígenos vivos para su uso en sistemas de vacunación masiva
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8962262B2 (en) * 2006-05-11 2015-02-24 Arbor Vita Corporation Method of protein extraction from cells
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
JP5916610B2 (ja) 2009-09-03 2016-05-11 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 直接的な化学的溶解のための方法および組成物
FI3831406T3 (fi) 2010-08-23 2024-08-06 Wyeth Llc Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2013132452A2 (en) 2012-03-09 2013-09-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
EP3583206A1 (en) 2017-02-17 2019-12-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Efficient cell free production of papillomavirus gene transfer vectors
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841708D1 (de) * 1997-02-06 2010-07-22 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
PL336715A1 (en) 1997-04-08 2000-07-03 Merck & Co Inc Stabilised formulation of human papilloma virus
CA2295316C (en) 1997-07-03 2007-06-26 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy

Also Published As

Publication number Publication date
FR07C0026I1 (nl) 2007-04-27
LU91327I2 (fr) 2007-05-14
NL300269I2 (nl) 2008-07-01
WO2000057906A1 (en) 2000-10-05
CY2007009I2 (el) 2010-07-28
JP2002540167A (ja) 2002-11-26
CY2007010I2 (el) 2009-11-04
LU91326I2 (fr) 2007-05-14
NL300268I1 (nl) 2007-05-01
DK1165126T3 (da) 2007-01-08
DE60030698D1 (de) 2006-10-26
ATE339222T1 (de) 2006-10-15
CY1105779T1 (el) 2010-07-28
JP4594534B2 (ja) 2010-12-08
LTC1165126I2 (lt) 2020-04-27
NL300270I1 (nl) 2007-05-01
CY2007008I2 (el) 2009-11-04
EP1165126B1 (en) 2006-09-13
DE122007000034I1 (de) 2007-08-09
ES2270822T3 (es) 2007-04-16
SI1165126T1 (sl) 2006-12-31
US6245568B1 (en) 2001-06-12
CY2007008I1 (el) 2009-11-04
DE122007000033I1 (de) 2007-08-09
CY2007010I1 (el) 2009-11-04
KR20020013516A (ko) 2002-02-20
LU91328I2 (fr) 2007-05-14
AU3909300A (en) 2000-10-16
PT1165126E (pt) 2006-12-29
LU91327I9 (nl) 2019-03-01
EP1165126A1 (en) 2002-01-02
CA2368391A1 (en) 2000-10-05
CA2368391C (en) 2011-06-07
LU91328I9 (nl) 2019-03-01
FR07C0026I2 (fr) 2012-08-03
CY2007009I1 (el) 2010-07-28
LU91326I9 (nl) 2018-12-31
LTPA2007002I1 (lt) 2020-03-25
DE122007000032I1 (de) 2007-08-09
US20010021385A1 (en) 2001-09-13
DE60030698T2 (de) 2007-07-19
AR023166A1 (es) 2002-09-04
AU778937B2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
NL300269I1 (nl) Werkwijze voor het vervaardigen van een humaan-papillomavirusvaccin met uiteengevallen en weer samengestelde virusachtige deeltjes.
EE04991B1 (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
AU2003227533A1 (en) Virus like particle from papillomavirus and their use in vaccine
AU2002241534A1 (en) Disposable aerosol generator system and methods for administering the aerosol
IL163814A0 (en) Virus-like particles of human papillomavirus
PT1465693E (pt) Sistema descartável gerador de aerossol e métodos para administrar o aerossol
EP1590451A4 (en) ALPHAVIRUS PARTICLES AND PREPARATION METHODS THEREOF
NL1028837A1 (nl) N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan.
HK1083749A1 (en) Solid nano pharmaceutical formulation and preparation method thereof
AU2002220151A1 (en) Method and system for the detection of heart disease
AU2003271021A1 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
IL169124A0 (en) Preparation and administration of hybrid cell vaccines for the prevention of cancer
AU2001266392A1 (en) The controlled release preparation of insulin and its method
NL1016891A1 (nl) Caloriearme notenboters en werkwijzen voor het bereiden daarvan.
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
WO2005123086A3 (en) Ziprasidone dosage form
AU2003278175A8 (en) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
AU2000279747A1 (en) Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion
AU2913400A (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
EP1567188A4 (en) MODIFIED VIRUS PARTICLES WITH IMMUNOGENIC PROPERTIES AND REDUCED LIPID CONTENT FOR THE TREATMENT AND PREVENTION OF INFECTION DISEASES
AU2273301A (en) Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer
AU2001269640A1 (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU2001289930A1 (en) Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
AU6964001A (en) Vaccine against the influenza virus and method for producing said virus vaccine